Skip to main content
. Author manuscript; available in PMC: 2010 Mar 16.
Published in final edited form as: Clin Pharmacol Ther. 2007 Sep 5;83(5):673–691. doi: 10.1038/sj.clpt.6100296

Figure 2.

Figure 2

Proposed molecular targets in cancer cells for the development of novel therapeutic strategies against aggressive and recurrent cancers. The schematic shows the possible antiproliferative and apoptotic effects induced by the tyrosine kinase activity inhibitors, including EGFR (gefitinib and erlotinib) and EGFR/erbB2/erbB3 (CI-1033), as well as by a selective inhibitor of SMO hedgehog signaling element (cyclopamine) and monoclonal antibody directed against Wnt and IGF-1R. Moreover, the reversal of the MDR mediated through ABC transporters by using specific transporter inhibitors and antibody directed against P-glycoprotein drug efflux pump is also shown. Cyt c, cytochrome c; PP2A, protein phosphatase 2A.